• Best stocks to buy now
  • Write for us
  • Contact
Sunday, April 18, 2021
  • ItalianoItaliano
Best Stocks
  • Home
  • Best stocks to buy nowHOT
  • Industries
    • All
    • 5g Stocks
    • Best Stocks to Buy Now
    • Marijuana Stocks
    • Penny Stocks
    • Tech stocks
    • Utility Stocks
    CTSH Stock

    Cognizant Technology Solutions Corp. stock (NGS: CTSH) rose 1% in a vacillating market after

    KLAC Stock

    Best stock 2020 KLA Corp. (NGS: KLAC) topped consensus expectations and reported year-over-year growth

    DHR Stock

    Could Danaher Corp. be among the best stocks to look at in Q3?

    Trending Tags

    • Donald Trump
    • Flat Earth
    • Golden Globes
  • News
  • Portfolio Tracker
  • Indices
  • Home
  • Best stocks to buy nowHOT
  • Industries
    • All
    • 5g Stocks
    • Best Stocks to Buy Now
    • Marijuana Stocks
    • Penny Stocks
    • Tech stocks
    • Utility Stocks
    CTSH Stock

    Cognizant Technology Solutions Corp. stock (NGS: CTSH) rose 1% in a vacillating market after

    KLAC Stock

    Best stock 2020 KLA Corp. (NGS: KLAC) topped consensus expectations and reported year-over-year growth

    DHR Stock

    Could Danaher Corp. be among the best stocks to look at in Q3?

    Trending Tags

    • Donald Trump
    • Flat Earth
    • Golden Globes
  • News
  • Portfolio Tracker
  • Indices
No Result
View All Result
Best Stocks
Home News

Integra Lifesciences Holdings is among the best stocks to buy right now

by Greg Sondergaard
January 23, 2021
in News
0
IART Stock

Source: Getty Images

26
SHARES
320
VIEWS
Share on FacebookShare on Twitter

INVESTMENT THESIS 

Integra Lifesciences Holdings Corp Stock
Source: Getty Images

We believe that the divestiture of the capital-intensive orthopedics business will lead to stronger organic revenue growth and margin expansion. We also believe that Integra is well positioned for stronger growth post-pandemic with help from increased regenerative tissue production capacity, recently acquired products, and continued expansion in overseas markets.

RECENT DEVELOPMENTS

Integra Lifesciences Holdings Stock
Source: Getty Images

We see Integra’s pending sale of its Extremity Orthopedics business to Smith & Nephew for $240 million as an addition by subtraction. By offloading the capital-intensive orthopedics business, which makes replacement joints for wrists, shoulders, ankles and feet, the company should be able to generate stronger revenue growth and increase profitability. Based on the company’s results over the past two years, the exclusion of orthopedics would have added approximately 50 basis points to organic growth, reduced operating expenses as a percentage of sales by 170 basis points, and increased the EBITDA margin by more than 140 basis points.

The orthopedics business simply did not have the size and scale to compete effectively in an industry that is consolidating around larger players.

Integra posted strong 3Q20 results on October 28 despite the impact of COVID-19. Adjusted EPS rose 17.6% to $0.80 and topped the consensus estimate by $0.26. GAAP net income was $32.3 million per share a year earlier. Revenue totaled $370.2 million, down 2.3% from the prior year as reported and 1.5% on an organic basis. At the same time, we note that revenue grew 43.1% sequentially.

While procedural volumes improved sequentially from 2Q20, the pace of improvement remains uncertain as hospital capacity is being increasingly strained by the surge in new coronavirus cases. 

By business segment, CSS revenue fell 5.4% to $239.3 million. CSS includes neurosurgery products and instruments. Revenue from the Orthopedics and Tissue Technologies segment rose to $130.9 million, up 3.8%. OTT includes the wound reconstruction and care business, private-label products, and the soon-to-be-divested extremity orthopedics.

Helped by a favorable geographic and product mix, careful expense management, and greater-than-expected revenue growth, the company achieved leverage in the income statement, boosting the 3Q adjusted gross margin by 160 basis points to 68.6%. The adjusted EBITDA margin was 27.9%, up 370 basis points. 

EARNINGS & GROWTH ANALYSIS 

Integra Lifesciences IART Stock
Source: Getty Images

It expects the OTT segment to continue to post year-over-year revenue growth in the U.S. The combination of growth in U.S. OTT and steady recovery in neurosurgery would enable Integra to post flat overall revenue in 4Q. Still, management remains cautious amid the current spike in COVID-19 cases in Europe, notably in France, Italy and Spain. If hospital capacity continues to be strained, Integra could see a mid-single-digit revenue decline.

Management expects the EBITDA margin to be sequentially lower in 4Q20, though still higher than in 4Q19. It plans to ease cost controls, likely resulting in slightly higher manufacturing expenses. 

FINANCIAL STRENGTH 

IART Integra Lifesciences Stock
Source: Getty Images

The stock does not pay a dividend.

MANAGEMENT & RISKS

Integra IART Stock
Source: Getty Images

Integra faces risks from the integration of acquired businesses and from disruptions to its manufacturing processes as it upgrades functionality and expands capacity. Given the impact of the pandemic on hospital procedures, Integra faces the risks of adjusting costs to reduced sales volume. At the same time, it must minimize disruptions to its manufacturing facilities and supply chain. The company also faces pricing pressure as hospitals seek to lower the cost of supplies, equipment and implants. Insurers may also seek to reduce reimbursement for certain surgical procedures.

COMPANY DESCRIPTION 

IART Integra  Stock
Source: Getty Images

Based in Plainsboro, New Jersey, Integra is an integrated medical device company that develops and markets devices for use in neurosurgery, wound repair, and the orthopedic reconstruction of joints in extremities such as shoulders, wrists, ankles and feet. The company’s products are used in cranial and spinal procedures, peripheral nerve repair, repair of skin and deeper tissue from burns and vehicular accidents, and the repair and reconstruction of soft tissue. The company also markets products through private-label relationships with larger medical device companies.

VALUATION 

Integra Lifesciences Holdings Corporation Stock
Source: Getty Images

IART trades at 18.9-times our 2021 EPS estimate, near the average of 19.0 for peers in our med-tech coverage universe. We believe this is an attractive valuation. As one of the smaller med-tech companies by market cap in our coverage universe, Integra is able to ‘move the needle’ on revenue and EPS growth through tuck-in M&A deals. 

On December 10, BUY-rated IART closed at $58.96, up $2.54.

Source: Argus

Tags: IARTIART StockIntegra Lifesciences Holdings CorpIntegra Lifesciences Holdings Corp Stock
Greg Sondergaard

Greg Sondergaard

Next Post
EXC Stock

Exelon Corp’s Stock Undervalued Compared To Dynegy?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

ENB Stock

Enbridge Stock (ENB): Financial Analysis And Forecast

2 months ago
BSX Stock

Boston Scientific Corp. shares (NYSE: BSX) fallen year-to-date on coronavirus concerns

3 weeks ago

Popular News

    Free Stocks Recommendations

    Get notified everytime we recommend a stock.
    Marketing by

    Best stocks to buy now

    Best-Stocks-Logo_dark

    We are a financial media dedicated to providing stock recommendations, news, and real-time stock prices.

    Industries

    Best stocks 5g stocks
    Best stocks to buy now
    Best gold stocks
    Best marijuana stocks
    Best penny stocks
    Best tech stocks
    Best utility stocks

    Quote

    Newsletter

    Get free stock recommendations and real-time news. Our portfolio has returned over 100% in 2020.

    Marketing by
    • Best stocks to buy now
    • Write for us
    • Contact

    © 2021 Best Stocks

    No Result
    View All Result
    • Home
    • Best stocks to buy now
    • Industry
      • Utility Stocks
      • Gold Stocks
      • Best Stocks to Buy Now
      • 5g Stocks
      • Tech stocks
      • Penny Stocks
    • News
    • Portfolio Tracker
    • Indices
    • English
    • Italiano

    © 2021 Best Stocks